Amgen Inc. $AMGN Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 655,511 shares of the medical research company’s stock after selling 4,482 shares during the quarter. Amgen makes up 2.2% of Sarasin & Partners LLP’s portfolio, making the stock its 18th biggest holding. Sarasin & Partners LLP’s holdings in Amgen were worth $214,555,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Laurel Wealth Advisors LLC increased its holdings in Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank purchased a new stake in shares of Amgen in the second quarter valued at about $1,663,726,000. Capital World Investors grew its position in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. National Bank of Canada FI grew its position in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.6%

Shares of NASDAQ AMGN opened at $347.80 on Friday. The firm has a market cap of $187.49 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 3.45 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm’s 50 day moving average price is $360.29 and its 200 day moving average price is $327.80.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the firm posted $5.31 EPS. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Ratings Changes

AMGN has been the subject of several research reports. Citigroup lifted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft boosted their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Cantor Fitzgerald upped their price objective on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.